SYRA earnings analysis
What we found in SYRA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Syra Health reported Q2 2026 revenue of $2.394 million, EPS of $0.02, and gross margin of 44.5%, with substantial improvement in profitability versus the prior comparable period. Year-to-date operating cash flow was $643,183, and management maintained its full-year profitability target for 2026. Sentiment remains neutral because operating performance improved, but management provided no new quantitative revenue or EPS guidance and highlighted revenue-recognition timing risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue grew 23% year over year
- Q2 2026 revenue was $2.394 million, up 23% year over year, indicating continued top-line growth despite potential contract-milestone timing variability.
- Margins and EPS improved materially
- Gross margin was 44.5% in Q2 2026, materially above the 17.8% reported in Q2 2024, while diluted EPS improved to $0.02 from $(0.21) in the comparable historical period.
- Returned to profitability
- The company reported net income of $250,242 for the period versus a net loss of $63,596 previously, marking a significant improvement in profitability.
- Positive year-to-date operating cash flow
- Operating cash flow was $643,183 for the first six months of 2026, providing positive liquidity generation during the year-to-date period.
- Controls remained effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes in internal control that materially affected, or were reasonably likely to materially affect, reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue timing may drive volatility
- Management stated that revenue-recognition timing and contract milestones may cause quarterly variability; this is material given Q2 revenue of $2.394 million and the company’s relatively small revenue base.
- Profitability target requires execution
- The company maintained its full-year profitability target for 2026, but execution remains a risk because the reported net income was $250,242 and profitability could be sensitive to contract timing and operating expenses.
- No new risk-factor disclosures
- No new quantified risk-factor changes were identified in Item 1A; the filing directs investors to the risk factors in the 2025 Form 10-K and notes that additional unknown risks may materially affect results.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.02
- Gross margin
- 44.5%
What they said about what is next.
Management maintained its previously stated target of full-year profitability for 2026. No quantitative revenue or EPS guidance was provided; management noted that revenue-recognition timing and contract milestones may cause quarterly variability.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Syra Health achieved notable improvements in Q1 2026, recording revenue of $2.27 million and a net income of $240,979, marking a significant turnaround from a net loss of $472,265 in the same quarter a year prior. The…
- 10-K · April 25, 2026
- Syra Health’s 10-K (and follow-up 10-K/A) show a company with declining revenue, limited market valuation and an auditor-level liquidity concern; the company reported fourth-quarter revenue of $1,734,000 and a GAAP…
- 10-K · March 12, 2026
- Syra Health positions itself as an integrated healthcare solutions provider with offerings across behavioral & mental health (flagship app Syrenity), population health, digital health, health education, and workforce…
- 10-Q · November 12, 2025
- Syra Health Corp. reported Q3 2025 revenues of $1,687,971, a decline from $2,253,336 in Q3 2024. The gross margin improved to 32.8% from 29.6% year-over-year, contributing to a narrowed net loss of $(225,902) versus…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SYRA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever